Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

At the 2018 European Hematology Association Congress, updates were presented on the ZUMA-1 trial. The ZUMA-1 trial examined the use of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (KTE-C19; axi-cel) in patients with refractory aggressive NHL. Results were previously published in the New England Journal of Medicine. Axi-cel demonstrated an objective response rate of 82% and a complete response rate of 54% in patients with NHL. Updated results show long-term responses, states Flinn.

Flinn says that the durability of remission was of particular interest, as the fall-off for response typically occurs within the first 3 months of treatment. If patients achieve a complete remission or a partial remission and keep that remission for 3 months, they are likely to maintain that response, explains Flinn.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.